When was Cardurion founded?

Cardurion was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Cardurion located?

Cardurion is headquartered in Boston, United States.

How many employees does Cardurion have?

As of Aug 31, 2026, the latest employee count at Cardurion is 75.

Is Cardurion a funded company?

Cardurion is a funded company, having raised a total of $270M across 5 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Apr 04, 2017.

When was the latest funding round of Cardurion?

Cardurion's latest funding was a $***** Series B round on Jul 10, 2024, with participation from 12 investors.

Where does Cardurion rank among its competitors?

Cardurion ranks 12th amongst 364 active competitors, of which 109 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of Cardurion?

Cardurion's top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

Cardurion - 2026 Company Profile, Team, Funding & Competitors

Cardurion is a series B company based in Boston (United States), founded in 2017 by Michael Mendelsohn. It operates as a Developer of therapeutics for heart and cardiovascular diseases. Cardurion has raised $270M in funding from investors like Polaris Partners, Bain Capital Private Equity and Bain Capital Life Sciences. The company has 364 active competitors, including 109 funded and 103 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Developer of therapeutics for heart and cardiovascular diseases. The propriety CRD-733, a PDE-9 inhibitor helps to improve cardiac function in heart failure patients and improves dysfunction in heart failure. The company is in its clinical stage of cardiovascular drug programs.

Website: cardurion.com
Email ID: *****@cardurion.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Boston, United States

Stage

Series B

Total Funding

$270M in 5 rounds

Latest Funding Round

Series B, Jul 10, 2024, $*****

Investors

Polaris Partners & 12 more

Ranked

12^th among 364 active competitors

Employee Count

75 as on Aug 31, 2026

Similar Companies

Tenaya Therapeutics & 346 more

View Cardurion's full profile

Cardurion has raised a total funding of $270M over 5 rounds. Its first funding round was on Apr 04, 2017. Its latest funding round was a Series B round on Jul 10, 2024 for $*****. 12 investors participated in its latest round. Cardurion has 13 institutional investors.

Here is the list of recent funding rounds of Cardurion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 10, 2024	2256692	Series B	7723833	9924255	6539434	7859431
Dec 30, 2022	4413811	Conventional Debt	9212208	3208424	7063200	2350063
Oct 29, 2021	3750944	Series B	8100760	5984851	Bain Capital Life Sciences & 1 more	4057551

Access funding benchmarks and valuations. Sign up today!

View details of Cardurion's funding rounds and investors

The founders of Cardurion is Michael Mendelsohn.

Here are the details of Cardurion's key team members:

Michael Mendelsohn: Founder & Chairman of Cardurion.
Contact Info: 1 email address

View details of Cardurion's Founder profiles and Board Members

Cardurion's employee count trend

Cardurion has 75 employees as of Aug 26. Here is Cardurion's employee count trend over the years:

Uncover Cardurion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cardurion include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Cardurion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RTW Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Venrock & 8 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Domain Associates & 16 others	66/100
7th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, Khosla Ventures & 7 others	65/100
8th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Quaker Partners Management ... & 4 others	64/100
9th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
10th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	62/100
12th	Cardurion 2017, Boston (United States), Series B	Developer of therapeutics for heart and cardiovascular diseases	$270M	Fidelity Investments, Bain Capital Life Sciences ... & 11 others	50/100